Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index; 10 of the 16 sources its claims cite were checked for support.
Abstract
Even though highly active anti-retroviral therapy is able to keep HIV-1 replication under control, the virus can lie in a dormant state within the host genome, known as a latent reservoir, and poses a threat to re-emerge at any time. However, novel technologies aimed at disrupting HIV-1 provirus may be capable of eradicating viral genomes from infected individuals. In this study, we showed the potential of the CRISPR/Cas9 system to edit the HIV-1 genome and block its expression. When LTR-targeting CRISPR/Cas9 components were transfected into HIV-1 LTR expression-dormant and -inducible T cells, a significant loss of LTR-driven expression was observed after stimulation. Sequence analysis confirmed that this CRISPR/Cas9 system efficiently cleaved and mutated LTR target sites. More importantly, this system was also able to remove internal viral genes from the host cell chromosome. Our results suggest that the CRISPR/Cas9 system may be a useful tool for curing HIV-1 infection.
Overview
CoChat Summary
TL;DR
The study shows that CRISPR/Cas9 targeting the HIV-1 LTR can disrupt proviral expression and excise integrated provirus in cell models. T5 gRNA targeting the TAR region was more effective than T6 targeting NF-κB, and repeated transfection improved suppression and excision.
Key findings
- In LTIG-transduced 293T cells, T5 gRNA reduced GFP-positive cells from 45.6% to 20.0% (p = 0.0003); triple transfection reduced GFP-positive cells from 40.8% to 2.1% (p = 0.0001).
- Sequence analysis found mutations in 18 of 22 HIV DNA clones, with 1–31-bp deletions from the putative cleavage site; two clones had deletion plus insertion mutations, consistent with NHEJ repair.
- In latent Jurkat clones c5 and c19, T5 reduced TNF-α-induced GFP-positive cells from 92.56% to 68.78% and from 98.48% to 66.95%, respectively; after three transfections in c19, reactivation fell from 97.8% to 35.5% (p = 0.00002).
- qPCR showed that on average 31.8% of provirus was excised after three transfections, and PCR detected a 1,067-bp footprint consistent with provirus excision leaving one LTR.
Methods
- Designed gRNA expression vectors targeting HIV-1 LTR: T5 against the TAR sequence in the R region and T6 against the NF-κB binding sequence in U3, co-transfected with human codon-optimized Cas9.
- Used HIV-1 provirus-integrated human cells: LTIG vector-transduced 293T and HeLa cells, plus Jurkat clones c5 and c19 that mimic HIV latency and were reactivated with TNF-α or 5-Aza-dC/TSA.
- Assessed GFP expression by flow cytometry, mutations by cloning and sequencing, proviral DNA amount by qPCR, and integration/excision by inverse PCR and flanking PCR; statistical analysis used Student’s t test.
Limitations
- The paper states that genome-editing and/or proviral excision efficiency should be quantified in HIV-infected primary cells, including latently infected CD4+ quiescent T cells.
- The paper states that an efficient delivery system must be developed and that possible off-target effects remain a concern for all genome-editing strategies.
- Evident from the text: most experiments use cell lines and engineered HIV vectors rather than primary patient cells; HeLa responses were modest, attributed to lower transfection efficiency and lower GFP expression; T6 was weaker because the 3′ NF-κB site may remain functional; and target-site mutations could allow some provirus to escape editing.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
10 Valid · 1 Not valid · 6 Not checked · 31 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“While highly active anti-retroviral therapy (HARRT) has dramatically decreased mortality from HIV-1 infection, there is currently no effective strategy to target the latent form of HIV-1 proviruses 5 .”
What the sources say
- Partly supportedcites [5] Eisele, E. & Siliciano, R. F. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity 37, 377–388 (2012). sourceExperimental — accuracy not yet measured
The Introduction describes the latent reservoir as a major barrier to HIV-1 eradication. In “The latent reservoir in resting CD4+ T cells,” the paper says reactivation alone may not purge that reservoir, but it also reports that SAHA can perturb it in vivo. Thus, the paper supports the lack of an established strategy to eliminate latent infection, not the categorical claim that no strategy effectively targets it. (LLM, conf=0.84)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Fortunately, the CRISPR/Cas9 system has the advantage in size compared with TALENs 22 .”
What the sources say
- Partly supportedcites [22] Gaj, T., Gersbach, C. A. & Barbas, C. F. 3rd. ZFN, TALEN and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. (2013). sourceExperimental — accuracy not yet measured
The Future directions section says the large size of TALENs may limit delivery by size-restricted vectors. It does not compare TALEN size with CRISPR/Cas9 size, so it supports the TALEN size concern but not the claimed comparative advantage. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Triple TF resulted in a significant decrease in the mean percentage of GFP positive cells from 40.8% to 2.1% ( p = 0.0001) was observed.”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In this study, we successfully disrupted the expression of HIV-1 provirus utilizing the CRISPR/Cas9 system ( Fig. 1 ).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A similar reduction in GFP expression was observed in c5 and c19 cells transfected with the T5 CRISPR/Cas9 system after 5-Aza-dC/TSA treatment ( Fig. 3A and B ).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
23 more claims
Create a free account to see all 48 claims and every source verdict.
- Probably not a substantial claim. 8
- It may state two separate claims as one. 14
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ebina et al. (2013) used calcium phosphate transfection to deliver plasmid DNA encoding Cas9 and sgRNA into latent HIV-1-infected human 293 T cells.”
From Delivering CRISPR: a review of the challenges and approaches (2018) · cites this paper as Ebina et al., 2013
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“various gene editing technologies have recently been shown to remove the proviral HIV-1 DNA from the host cell genome by targeting its highly conserved 5′ and 3′ long terminal repeats (LTRs)”
From RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection (2014) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“With the appropriate guide RNA, the Cas9 enzyme can recognize and cleave virtually any viral genome (29).”
From RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection (2014) · cites this paper as [29]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Off-target effects refer to the possibility that the CRISPR/Cas9 system may cut DNA at a non-specific location other than the target DNA, resulting in unwanted gene mutations or interference with normal gene function [10].”
From A Review of Research on CRISPR/Cas9 Gene Editing Technology in Disease Treatment (2024) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“However, this proof of concept is certainly applicable to any other cell type, including T-lymphoid cells (Fig. S6) (12,13), astrocytes, and neural stem cells”
From RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection (2014) · cites this paper as [12]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering
Gaj, T., Gersbach, C. A., & Barbas, C. F. (2013) · Trends in Biotechnology · doi:10.1016/j.tibtech.2013.04.004 · Cited by 3,820
Gasiunas, G., Barrangou, R., Horvath, P., & Siksnys, V. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1208507109 · Cited by 2,769
Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease
Cho, S. W., Kim, S., Kim, J. M., & Kim, J.-S. (2013) · Nature Biotechnology · doi:10.1038/nbt.2507 · Cited by 1,863
RNA-guided genetic silencing systems in bacteria and archaea
Wiedenheft, B., Sternberg, S. H., & Doudna, J. A. (2012) · Nature · doi:10.1038/nature10886 · Cited by 1,851
Highly efficient endogenous human gene correction using designed zinc-finger nucleases
Urnov, F. D., Miller, J. C., Lee, Y.-L., Beausejour, C. M., Rock, J. M., Augustus, S., Jamieson, A. C., Porteus, M. H., Gregory, P. D., & Holmes, M. C. (2005) · Nature · doi:10.1038/nature03556 · Cited by 1,641
Makarova, K. S., Grishin, N. V., Shabalina, S. A., Wolf, Y. I., & Koonin, E. V. (2006) · Biology Direct · doi:10.1186/1745-6150-1-7 · Cited by 1,199
Development of a self-inactivating lentivirus vector
Miyoshi, H., Blömer, U., Takahashi, M., Gage, F. H., & Verma, I. M. (1998) · Journal of Virology · doi:10.1128/jvi.72.10.8150-8157.1998 · Cited by 1,196
HIV reproducibly establishes a latent infection after acute infection of T cells in vitro
Jordan, A., Bisgrove, D., & Verdin, E. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg188 · Cited by 914
Cited by
Items 401–500 of 562
Liao, H., Li, M., Martinez, L. M., & Belmonte, J. C. I. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1046791 · Cited by 4
Popova, M. O., Sergeev, V. S., Lepik, K. V., Shakirova, A. I., Potter, A. Y., Barhatov, I., Fehse, B., & Afanasyev, B. V. (2017) · Journal Infectology · doi:10.22625/2072-6732-2017-9-1-31-39 · Cited by 4
Precision Medicine and Challenges in Research and Clinical Implementation
Haga, S. B. (2017) · Principles of Gender-Specific Medicine · doi:10.1016/b978-0-12-803506-1.00021-8 · Cited by 5
Smith, L. M., Ladner, J. T., Hodara, V. L., Parodi, L. M., Harris, R. A., Callery, J. E., Lai, Z., Zou, Y., Raveedran, M., Rogers, J., et al. (2021) · Journal of Virology · doi:10.1128/jvi.00882-21 · Cited by 6
Centner, C. S., Moore, J. T., Baxter, M. E., Yaddanapudi, K., Bates, P. J., & Kopechek, J. A. (2022) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2022.08.005 · Cited by 4
Cell-based gene therapy against HIV
Dey, R., & Pillai, B. (2015) · Gene Therapy · doi:10.1038/gt.2015.58 · Cited by 6
CRISPR/Cas-9 System: Magnificent Tool for Genome Editing
Vasdev, K. (2017) · International Journal of Biotechnology and Bioengineering · doi:10.25141/2475-3432-2017-9.0293 · Cited by 3
Zhen, S., Lu, J., Ling, H., Liu, Y., Chen, W., & Li, X. (2018) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2018.10.004 · Cited by 3
RetractedTowards a novel therapy against AIDS
Locatelli, A. (2020) · Medical Hypotheses · doi:10.1016/j.mehy.2020.109569 · Cited by 4
Engineering Sequence-Specific DNA Binding Proteins for Antiviral Gene Editing
Arbuthnot, P. B. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-410518-8.00003-x · Cited by 5
Esmaeilzadeh, A., & Farshbaf, A. (2015) · Journal of Genetic Syndromes & Gene Therapy · doi:10.4172/2157-7412.1000e130 · Cited by 4
“Furthermore, another nuclease such as CRISPR/Cas9 (Clustered regularly interspaced palindromic repeats/CRISPR associated gene) could modify viral genome to inhibition of viral integration, gene expression and replication [25,26].”
BackgroundCRISPR-Cas9 technology: a breakthrough in cancer gene therapy
Jameel, Z. I. (2026) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-025-00833-1 · Cited by 5
“Hence, they are great vehicles for disseminating CRISPR/Cas9 components [73].”
Lessons From HIV-1 Gene Therapy in Humanized Mice: Is Targeting Viral Entry the Road to Success?
Petit, N. Y., & Marodon, G. (2016) · Current Gene Therapy · doi:10.2174/1566523216666160104141644 · Cited by 3
“Provirus was also targeted in vitro by CRISPR/Cas9 or by TALEN [76,77].”
MethodInfluentialIn pursuit of an HIV cure: from stem cell transplants to gene therapies
Clees, J., Basic, M., Cruz, P. E., Ramirez, S. H., & Andrews, A. M. (2025) · Frontiers in Genome Editing · doi:10.3389/fgeed.2025.1634193 · Cited by 5
Perspectives of Genome-Editing Technologies for HIV Therapy
Ebina, H., Gee, P., & Koyanagi, Y. (2015) · Current HIV Research · doi:10.2174/1570162x13666150807105718 · Cited by 4
“With this strategy in mind, our group validated the HIV proviral-editing strategy using the CRISPR/Cas9 system [25].”
MethodSelf-citationSampath, R., Cummins, N. W., Natesampillai, S., Bren, G. D., Chung, T. D. Y., Baker, J. V., Henry, K., Pagliuzza, A., & Badley, A. D. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179327 · Cited by 3
Therapeutic Gene Editing in Muscles and Muscle Stem Cells
Tabebordbar, M., Cheng, J. K. W., & Wagers, A. J. (2017) · Research and perspectives in neurosciences · doi:10.1007/978-3-319-60192-2_10 · Cited by 3
“Moreover, CRISPR-Cas9 can be used to directly target and disrupt integrated proviral genomes (Vulin et al. 2012; Ebina et al. 2013; Kennedy and Cullen 2015; Wang et al. 2015).”
BackgroundAu, T. Y., Arudkumar, J., Assavarittirong, C., & Benjamin, S. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01129-7 · Cited by 3
“Excit-ingly, the authors were able to excise the integrated proviral genome from the host chromosome of HIV-infected cells [8].”
Defining the Effects of PKC Modulator HIV Latency-Reversing Agents on Natural Killer Cells
Dimapasoc, M., Moran, J. A., Cole, S., Ranjan, A., Hourani, R., Kim, J. T., Wender, P. A., Marsden, M. D., & Zack, J. A. (2024) · Pathogens and Immunity · doi:10.20411/pai.v9i1.673 · Cited by 3
Advancing towards HIV-1 remission: Insights and innovations in stem cell therapies
Chatterjee, A., Matsangos, A. E., Latinovic, O., Heredia, A., & Silvestri, G. (2024) · Archives of Stem Cell and Therapy · doi:10.46439/stemcell.5.020 · Cited by 5
“These advances in gene therapy could revolutionize the field by creating a renewable source of HIV-resistant immune cells that could potentially eradicate or control viral reservoirs more effectively than current therapies [20].”
BackgroundGenome editing for the treatment of tumorigenic viral infections and virus-related carcinomas
Yu, L., Tian, X., Gao, C., Wu, P., Wang, L., Feng, B., Li, X., Wang, H., Ma, D., & Hu, Z. (2018) · Frontiers of Medicine · doi:10.1007/s11684-017-0572-1 · Cited by 3
“During the HIV-1 life cycle, retroviral DNA must integrate into the host cell genome [77].”
BackgroundInfluentialCan Designer Indels Be Tailored by Gene Editing?
Trimidal, S. G., Benjamin, R., Bae, J. E., Han, M., Kong, E., Singer, A., Williams, T. S., Yang, B., & Schiller, M. R. (2019) · BioEssays · doi:10.1002/bies.201900126 · Cited by 4
Arbuthnot, P. B. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-410518-8.00012-0 · Cited by 3
Gene editing based hearing impairment research and therapeutics
Kang, W., Sun, Z., Zhao, X., Wang, X., Tao, Y., & Wu, H. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134326 · Cited by 4
The Potential Contribution of Caveolin 1 to HIV Latent Infection
Sahay, B., & Mergia, A. (2020) · Pathogens · doi:10.3390/pathogens9110896 · Cited by 4
Running with (CRISPR) Scissors: Tool Adoption and Team Assembly
Zyontz, S. (2019) · Academy of Management Proceedings · doi:10.5465/ambpp.2019.17964abstract · Cited by 3
““Capturing technological opportunity via Japan’s star scientists: Evidence from Japanese firms’ biotech patents and products.””
From bench to bedside: stem cell therapy as a transformative approach against HIV
Ankit Kumar Bharti, S., Mukherjee, A. G., Gopalakrishnan, A. V., Gajendran, B., Vashishth, R., & Prince, S. E. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-11586-4 · Cited by 2
The applications and advances of CRISPR-Cas9 in medical research
Lu, X., Sun, H., Xu, Y. J., Xi, Y., & Gu, B. (2016) · Briefings in Functional Genomics · doi:10.1093/bfgp/elw036 · Cited by 3
Introduction to Synthetic Biology
Singh, V. (2020) · Springer eBooks · doi:10.1007/978-981-15-0081-7_1 · Cited by 3
Treatment of infectious diseases by in vivo gene editing
Wu, Y., & Zhang, H. (2023) · National Science Open · doi:10.1360/nso/20220061 · Cited by 5
A Primer on Gene Editing: What Does It Mean for Pathologists?
Cushman‐Vokoun, A. M., Schmidt, R. J., Hiemenz, M., Fung, M. K. Y., Zhang, B. M., Bradshaw, G., Gandhi, M. J., Yao, J., Yohe, S. L., Beckman, A. K., et al. (2023) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2022-0410-cp · Cited by 2
Biosafety and biosecurity consideration in CRISPR-Cas
Hassan, N., Ali, H., Hassan, F., Ali, H., & Tawab, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13229-2.00018-1 · Cited by 4
Falah, G., Sharvit, L. E., & Atzmon, G. (2024) · Experimental Gerontology · doi:10.1016/j.exger.2024.112586 · Cited by 2
“These cells are frequently employed in CRISPR/Cas9 gene-knocking research (Ebina et al., 2013; Chen et al., 2013).”
CRISPR/Cas9 Reduces Viral Load in a BALB/c Mouse Model of Ocular Herpes Infection
Garcia, L. S., de Sousa, R. M. P., de Campos, V. S., Ferreira, E. M., Cascabulho, C. M., de Souza, E. M., & de Paula, V. S. (2025) · Biomedicines · doi:10.3390/biomedicines13071738 · Cited by 3
“For viruses, studies addressing human immunodeficiency virus (HIV) treatment are more advanced [17–20].”
Welcome to the Brave New World: CRISPR Mediated Genome Editing?pathway to Designer Babies?
Elizondo, D. M., Fernando, L. M., Oliver, E., Clinton, K., Retland, N., Paturault, H., & Ullah, H. (2015) · Plant Tissue Culture and Biotechnology · doi:10.3329/ptcb.v25i1.24132 · Cited by 3
CRISPR-Cas-Based Gene Therapy to Target Viral Infections
Hussein, M., Berkhout, B., & Herrera-Carrillo, E. (2022) · Springer eBooks · doi:10.1007/978-3-030-93333-3_5 · Cited by 2
Novel Prospective Treatment Options
Stanley, J., & Yamamoto, N. (2015) · InTech eBooks · doi:10.5772/60961 · Cited by 2
“In vitro studies employing the CRISPR/Cas9 system have demonstrated the ability of the technique to remove the HIV internal genes and suppress proviral reactivation in T cells [138].”
BackgroundThe CRISPR-Cas9 System: A New Dawn in Gene Editing
Saleem, N. H. M. (2014) · OMICS Journal of Radiology · doi:10.4172/1948-593x.1000109 · Cited by 4
“They found that the CRISPR- Cas9 system is able to remove internal viral genes from the host cell chromosome [44].”
BackgroundGenome editing with programmable site-specific nucleases
Yamamoto, T., Sakamoto, N., & Sakuma, T. (2014) · Uirusu · doi:10.2222/jsv.64.75 · Cited by 2
Microbial genome engineering for promoting health and understanding disease
Fehér, T., & Györfy, Z. (2015) · Repository of the Academy's Library (Library of the Hungarian Academy of Sciences) · Cited by 2
Genome engineering technologies for targeted genetic modification in plants
Tang, W., & Tang, A. Y. (2018) · Journal of Forestry Research · doi:10.1007/s11676-017-0588-z · Cited by 2
“The CRISPR/Cas9 system has been used to edit the genome and block gene expression and thus may be a powerful tool to protect against pathogens (Ebina et al. 2013).”
MethodEmerging CRISPR/Cas9 applications for T-cell gene editing
Preece, R., & Georgiadis, C. (2019) · Emerging Topics in Life Sciences · doi:10.1042/etls20180144 · Cited by 3
“Transfection of CRISPR reagents into a T cell line transduced with an inducible GFP expressing lentiviral vector, resulted in >60% reduction of reporter expression [111].”
BackgroundInfluentialAn introduction and use of the CRISPR-Cas systems
Singh, V. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2020.12.011 · Cited by 3
Advances in HIV Eradication Strategies
Mei, Q., Wang, W., Wu, J., & Gao, Y. (2022) · Infectious Microbes & Diseases · doi:10.1097/im9.0000000000000088 · Cited by 2
“sites and great loss of LTR-driven expression.(54) It has also been shown that CRISPR/Cas9 technology can increase the function of HIV-infected CD4 T cells after removing hyaluronic acid from fibroblasts.”
BackgroundThe Function of the XlnR Transcription Factor in the Filamentous Fungus Penicillium verruculosum
Kislitsin, V. Y., Chulkin, A. M., Zorov, I. N., et al. (2023) · Applied Biochemistry and Microbiology · doi:10.1134/s0003683823090053 · Cited by 2
“Works carried out using CRISPR/Cas9 were first published in 2013 [2, 3].”
Advancements of CRISPR/Cas9 technology and its value in antiviral therapeutics
Dev, K., Begum, J., Mir, N. A., & Kant, R. (2021) · Letters In Animal Biology · doi:10.62310/liab.v1i1.60 · Cited by 1
Leukemia and Retroviral Disease
Loarca, L., Sullivan, N. T., Pirrone, V., & Wigdahl, B. L. (2015) · InTech eBooks · doi:10.5772/61254 · Cited by 3
“Clearly, this is exciting technology with great promise to completely eliminate latent or persistent viral infections without having to activate latent viral gene expression to kill latently infected cells [125–130, 152].”
BackgroundCRISPR Genome Editing Technology and its Application in Genetic Diseases: A Review
Khatibi, S., Sahebkar, A., & Aghaee‐Bakhtiari, S. H. (2020) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201021666200621161610 · Cited by 3
CRISPR/Cas9-based genome engineering in HIV gene therapy
Tang, X. (2021) · E3S Web of Conferences · doi:10.1051/e3sconf/202123302004 · Cited by 2
Hillman, T. (2019) · Preprints.org · doi:10.20944/preprints201907.0211.v1 · Cited by 1
Shahzaib, M., Brügmann, T., Shakeel, M., Khan, S. H., Azhar, M. T., Atif, R. M., Fladung, M., & Rana, I. A. (2023) · Preprints.org · doi:10.20944/preprints202305.1887.v1 · Cited by 3
Treatment of Adamantinomatous Craniopharyngioma Using RNAi and CRISPR Targeting the WNT PathwayPreprint
Gokul, S., & Gokul, M. (2024) · Preprints.org · doi:10.20944/preprints202404.0053.v1 · Cited by 1
CRISPR/Cas-based diagnosis and treatment of infectious diseases
Wang, X., Lǐ, Y., & Huang, X. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-818619-0.00077-0 · Cited by 2
The CRISPR Revolution: Can We Change Genes for the Better?
Doudna, J. A. (2024) · Frontiers for Young Minds · doi:10.3389/frym.2024.1063878 · Cited by 1
“AIDS is caused by a virus called HIV, which CRISPR can target to remove the HIV DNA from the patient’s cells [7].”
Singh, R., Pandey, S., Pandey, A., & Kumar, G. (2025) · CABI biotechnology series. · doi:10.1079/9781800626638.0001 · Cited by 2
Highly stable Cas9 promotes HBV genome destruction by antagonizing HSC70-mediated degradation
Li, Z., Song, Y., Huang, H., Chen, R., Liu, M., Yang, X., Luo, Z., Liu, B., & Wang, J. (2025) · Emerging Microbes & Infections · doi:10.1080/22221751.2025.2556728 · Cited by 2
Targeting human oncogenic viruses with CRISPR/Cas: New therapeutic opportunities and challenges
Jigheh, M. P., Ravanlo, Z. Z., Shahrak, M. Z., Mohabbat, A., & Baghi, H. B. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119284 · Cited by 1
Editing Cultured Human Cells: From Cell Lines to iPS Cells
Li, H. L., & Hotta, A. (2014) · Springer eBooks · doi:10.1007/978-4-431-55227-7_3 · Cited by 1
The Current State-of-the-Art in Therapeutic Genome Editing and the Future
Manesh, D. M., & Malik, P. (2016) · Gene Technology · doi:10.4172/2329-6682.1000135 · Cited by 1
Modeling Cancer Using CRISPR-Cas9 Technology
Rodríguez, S., Martínez-Lage, M., & Torres-Ruiz, R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809468-6.00034-6 · Cited by 3
Harnessing the potential of CRISPR-Cas9 to advance the study of human fungal pathogens
McCarthy, M. W., & Walsh, T. J. (2017) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2017.1375851 · Cited by 1
Excision of latent HIV-1: CRISPR technology overcomes viral strain diversity
Bunnell, B. A. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103720 · Cited by 1
(2014) · Microbiology Australia · doi:10.1071/mav35n2 · Cited by 1
Prospects for using CRISPR-Cas9 system in the treatment of human viral diseases
Зиганшин, А. М., Рамильевич, М. А., Абдурахманович, О. М., Мудров, В. А., & Khalitova, R. S. (2023) · Бюллетень Восточно-Сибирского научного центра Сибирского отделения Российской академии медицинских наук · doi:10.29413/abs.2023-8.1.5 · Cited by 2
The Applications of the CRISPR/Cas9 Gene-Editing System in Treating Human Diseases
Varanasi, A., & Wilson, E. (2022) · Journal of Student Research · doi:10.47611/jsrhs.v11i3.3166 · Cited by 3
Burgeoning therapeutic strategies to curb the contemporary surging viral infections
Akram, F., Waheed, H. M., Shah, F. I., Haq, I. U., Nasir, N., Akhtar, M. T., & Gohar, U. F. (2023) · Microbial Pathogenesis · doi:10.1016/j.micpath.2023.106088 · Cited by 1
Precision medicine: Overview and challenges to clinical implementation
Haga, S. B. (2023) · Principles of Gender-Specific Medicine · doi:10.1016/b978-0-323-88534-8.00020-1 · Cited by 2
HIV-1 mRNA knockdown with CRISPR/CAS9 enhances neurocognitive function
McLaurin, K. A., Li, H., Khalili, K., Mactutus, C. F., & Booze, R. M. (2024) · Journal of NeuroVirology · doi:10.1007/s13365-024-01193-z · Cited by 4
“…of single gRNA molecules to target the flanking HIV-1 long terminal repeat (LTR) sequences provided a fundamental proof-of-concept, whereby treatment cleaved viral DNA in vitro and inhibited viral gene expression (Ebina et al. 2013; Hu et al. 2014; Kaminski et al. 2016a; Yin et al. 2016).”
BackgroundTyagi, P., & Tyagi, M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99744-7.00007-9 · Cited by 1
Strategies for HIV-1 elimination
Zhang, C., Waight, E. M., & Dash, P. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99744-7.00019-5 · Cited by 1
CRISPR/Cas9 for Genome Engineering: the Next Genomic Revolution
Zhang, Y., Yeo, W. S., Ng, K. H., & Yap, H. (2015) · Journal of Biochemistry and Molecular Biology Research · Cited by 2
Using Engineered Nucleases to Create HIV-Resistant Cells
Llewellyn, G. N., Exline, C. M., Holt, N. G., & Cannon, P. M. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-3509-3_10 · Cited by 1
Treating Genetic Disorders Using State-Of-The-Art Technology
Jamal, M., Ullah, A., Ahsan, M., Tyagi, R., Habib, Z., Khan, F. A., & Rehman, K. (2017) · Current Issues in Molecular Biology · doi:10.21775/cimb.026.033 · Cited by 1
Biomolecular Therapeutics for HIV
Li, S., & Burnett, J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-50878-0.00018-5 · Cited by 1
Exploring the potential of CRISPR-Cas9 for the removal of human viruses
Panchasara, H., Patel, S. K., & Singh, V. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818140-9.00003-9 · Cited by 2
AIDS tedavisi için gen düzenleme çalışmaları
Akpınaroğlu, C. (2020) · Gene Editing · doi:10.29228/genediting.40387 · Cited by 1
“Ebina et al. (2013), have delivered via transfection CRISPR and Streptococcus pyogenes Cas9 (SpCas9) in 2013 while working with 293T, HeLa, Jurkat cells and they managed to suppress HIV-1 genes’ expression successfully when targeting HIV-1 LTR in Jurkat cells (Ebina, et al. 2013).”
CRISPR-Cas9 for therapy: the challenges and ways to overcome them
Acharya, S., Maiti, S., & Chakraborty, D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818140-9.00009-x · Cited by 3
CRISPER-RNA Guided Gene Editing and Implications in Endogenous Genes Activation
Qamar, M., Tanvir, K., Akbar, S., Ghani, U., Ali, H., Bilal, M., Rehman, A., Arif, Z., & Batool, S. (2020) · Scholars International Journal of Biochemistry · doi:10.36348/sijb.2020.v03i03.006 · Cited by 1
“In addition, this system has been shown to delete viral genes from the host cell chromosome [41] Cas9/sgRNAs efficiently inactivate HIV gene expression and replication in latently infected cells, including microglial, promonocytic and T cells.”
Role of CRISPR-Cas/9 in Hematological Disorders: A Review
Sharma, S. (2021) · Archives in Biomedical Engineering & Biotechnology · doi:10.33552/abeb.2021.05.000613 · Cited by 1
Stem Cell Engineering Developments And Advances In Providing HIV Immunity
DeSimone, J., & Gallicchio, V. S. (2021) · Journal Of Stem Cell Research · doi:10.52793/jscr.2021.2(2)-23
“al used CRISPR/Cas9 to target latent provirus using gRNAs that recognize the LTR of HIV and reduced levels of provirus in Jurkat cells by 30% [67].”
MethodReplication-Competent Reporter-Expressing Viruses
Martínez‐Sobrido, L. (2016) · MDPI eBooks · doi:10.3390/books978-3-03842-259-4 · Cited by 1
Halim, S. N. A. A., Feizal, N. N., Najmi, A. S. A., Omar, R. N. C., & Hatta, F. H. M. (2022) · Current Applied Science and Technology · doi:10.55003/cast.2022.06.22.014 · Cited by 5
CRISPR/Cas, a powerful tool for genome editing in ornamental plants
Sarmast, M. K., & گرگان, د. ع. ک. و. م. ط. (2021) · Flower and Ornamental Plants · doi:10.52547/flowerjournal.6.1.37 · Cited by 1
“Cas سوریو ربارب رد ینمیا داجیا اب هطبار رد هتخانش اه،دش نیا سوریو ییاهتنا دنلب یرارکت یحاون رد شهج داجیا و تسکش یارب متسیسHIV-1 نژ فذح نینچمه و زا یلخاد یسوریو یاه موزومورکهتخای( تسا هتفر راک هب هدولآ یاهEbina et al., 2013 .)”
Volotovski, I. D., & Poleshko, А. G. (2018) · Proceedings of the National Academy of Sciences of Belarus Biological Series · doi:10.29235/1029-8940-2018-63-1-113-125 · Cited by 1
Latent HIV-1 provirus in vitro suppression using combinatorial CRISPR/Cas9 strategy
Kalidasan, V., Ravichantar, N., Besari, A. M., Yunus, M. A., Yusoff, N. M., Mohamed, Z., & Das, K. T. (2022) · Gene Reports · doi:10.1016/j.genrep.2022.101686 · Cited by 1
Precision Genome Editing for Systems Biology – A Temporal Perspective
Völlmy, F., & Linding, R. (2017) · Systems Biology · doi:10.1002/9783527696130.ch14 · Cited by 1
Type I-E CRISPR-Cas system as an immune system in a eukaryotePreprint
Rath, D., Amlinger, L., Bindal, G., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/357301 · Cited by 1
Bioengineering of novel 3D scaffolds for cell-based therapy in heart failure and diabetes mellitus
Sondermeijer (2019) · Research Publications (Maastricht University) · doi:10.26481/dis.20190517hs
Hillman, T. (2020) · Preprints.org · doi:10.20944/preprints201907.0211.v2
Chávez, L., Reddy, N. R., Raymond, K. A., Bouzidi, M. S., Desai, S., Dossani, Z. Y., Sperber, H. S., Theiler, J. P., Korber, B., & Pillai, S. K. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.10.243329 · Cited by 1
Klinnert, S., Freitag, P. C., Plückthun, A., & Metzner, K. J. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.18.572146 · Cited by 1
“The gRNA–TAR tested in this work and previous studies targets the TAR sequence in the LTR R region, which is positioned at the neck of the stem loop region of TAR and is critical for Tat– TAR complex formation and initiation of HIV-1 transcription 10,21,23,24,34 .”
BackgroundMethodA Review of Research on CRISPR/Cas9 Gene Editing Technology in Disease Treatment
Jing, X. (2024) · Academic Journal of Science and Technology · doi:10.54097/5crj2x50
“Off-target effects refer to the possibility that the CRISPR/Cas9 system may cut DNA at a non-specific location other than the target DNA, resulting in unwanted gene mutations or interference with normal gene function[10].”
CRISPR-CAS SYSTEM: A FEASIBLE SOLUTION FOR GETTING RID OF PERSISTENT VIRAL INFECTION?
Zhong, Z. (2014) · Current Research in Virology · doi:10.3844/ajvsp.2014.6.7
“Indeed, studies showed that Cas9/sgRNAcan be adapted for disrupting the LTR elements of Human Immunodeficiency Virus (HIV) provirus and causing a significant loss of LTR-driven expression (Ebina et al., 2013).”
BackgroundChallenges, progress and strategies in the search for a cure for HIV
Chang, C. C., & Lewin, S. R. (2014) · Microbiology Australia · doi:10.1071/ma14023
Gene Correction Technology and Its Impact on Viral Research and Therapy
Lee, G. H., & Aung, M. M. (2016) · InTech eBooks · doi:10.5772/62231 · Cited by 1
“CCR5, which encodes a coreceptor for HIV entry [88, 89], has been a popular target for developing a new generation of HIV therapy for several reasons.”
Background[Biologic treatments for hereditary diseases].
Yang, J., Xie, Y., & Chen, L. (2015) · PubMed
Gene Therapy for HIV-1 Infection
Arbuthnot, P. B. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-410518-8.00008-9
Progress of genome editing approaches towards gene therapy
Ji, H., & Zhu, H. (2015)
DeSimone, M. F., Dampier, W., & Saçan, A. (2015) · iDEA - Drexel University Institutional Repository · doi:10.17918/etd-6497
Metadata
- Authors
- Ebina, H., Misawa, N., Kanemura, Y., & Koyanagi, Y.
- Affiliations
- Kyoto University (JP)
- Corresponding author
- Ebina, Hirotaka
- Venue
- Scientific Reports
- Published
- 2013-08-26
- Volume
- 3
- Issue
- 1
- Pages
- 2510-2510
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC3752613
- OpenAlex
- W1966452674
- Cited by
- 565
- References
- 28
- Citations by year
- 2026: 13 · 2025: 19 · 2024: 39 · 2023: 28 · 2022: 50 · 2021: 52 · 2020: 51 · 2019: 35 · 2018: 46 · 2017: 58 · 2016: 73 · 2015: 61 · 2014: 36 · 2013: 3
- FWCI
- 25.82
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/3.0/ (tdm)
- creativecommons.org/licenses/by/3.0/ (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion)
- Kyoto University Research Information Repository (Kyoto University) (submittedVersion, cc-by)
- Funders
- Ministry of Education, Culture, Sports, Science and Technology (24115008)
- Japan Society for the Promotion of Science (24790438, 24390112)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- CRISPR/Cas9, HIV-1 provirus, latent HIV-1 reservoir, HIV-1 latency, HIV-1 cure, genome editing, T cells, HIV-1 reactivation
- MeSH terms
- HeLa Cells, Humans, HIV-1, HIV Long Terminal Repeat, Virus Latency, Gene Silencing, HEK293 Cells, CRISPR-Cas Systems, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-27, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-27 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.